PUBLISHER: QYResearch | PRODUCT CODE: 1867588
PUBLISHER: QYResearch | PRODUCT CODE: 1867588
The global market for Total Artificial Heart was estimated to be worth US$ 641 million in 2024 and is forecast to a readjusted size of US$ 1551 million by 2031 with a CAGR of 13.5% during the forecast period 2025-2031.
This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Total Artificial Heart cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
Total Artificial Heart (TAH) is a prosthetic device that is implanted into the body to replace the biological heart. A few proprietary artificial heart devices have been developed including the Syncardia TAH, AbioCor (Abiomed, Danvers, Massachusetts, USA), and CARMAT (Carmat, Velizy, France). The history of these devices and their clinical use has recently been reviewed. Among the devices listed, the Syncardia (TAH) is the only device currently in use. The CARMAT is currently undergoing feasibility studies, however, data has been limited to a handful of patients thus far. There is also no data on the use of the AbioCor or CARMAT in patients with CHD.
The Total Artificial Heart (TAH) market is experiencing rapid growth. This growth is primarily driven by several factors: first, the increasing incidence of cardiovascular diseases, particularly among the elderly population, leading to a rise in end-stage heart failure patients. Second, the shortage of heart transplant donors makes TAH an effective alternative, especially as a bridging therapy. Third, advancements in TAH technology, including miniaturization and improved durability and reliability, have made it a viable clinical option. Additionally, governmental and healthcare institutions' emphasis on cardiovascular disease treatment and insurance coverage for high-cost therapies have supported the development of the TAH market.
Despite the promising outlook, the TAH market faces several challenges and risks. First, the high cost of TAH limits its accessibility, particularly in developing countries. Second, long-term use of TAH may be associated with complications such as infections, thrombosis, and mechanical failures, impacting patient quality of life and treatment outcomes. Third, the complexity of TAH implantation surgery requires specialized medical teams, and postoperative management demands significant resources. Furthermore, the lifestyle changes required for long-term TAH use, including mobility restrictions and psychological adaptation, need to be carefully considered in patient care.
As TAH technology matures and clinical applications expand, downstream demand is becoming more diversified. Hospitals and medical centers, particularly heart transplant centers and intensive care units, are increasing their demand for TAH. Insurance companies are gradually expanding coverage for TAH, improving its accessibility for patients. Additionally, patient preferences for high-quality life have made comfort and convenience important considerations in TAH design and development. With the global aging population and the high incidence of cardiovascular diseases, the demand for TAH is expected to continue growing, establishing it as a crucial component in the treatment of heart failure in the coming decades.
This report aims to provide a comprehensive presentation of the global market for Total Artificial Heart, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Total Artificial Heart by region & country, by Type, and by Application.
The Total Artificial Heart market size, estimations, and forecasts are provided in terms of sales volume (Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Total Artificial Heart.
Market Segmentation
By Company
Segment by Type
Segment by Application
By Region
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Total Artificial Heart manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Total Artificial Heart in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Total Artificial Heart in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.